In last trading session, Ocugen Inc. (NASDAQ:OCGN) saw 90,368,058 shares changing hands with its beta currently measuring 4.45. Company’s recent per share price level of $10.91 trading at -$1.6 or -12.79% at ring of the bell on the day assigns it a market valuation of $2.05 Billion. That closing price of OCGN’s stock is at a discount of -72.04% from its 52-week high price of $18.77 and is indicating a premium of 98.44% from its 52-week low price of $0.17. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 19.33 Million shares which gives us an average trading volume of 59.1 Million if we extend that period to 3-months.
For Ocugen Inc. (OCGN), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.2. Splitting up the data highlights that, out of 4 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0.49 in the current quarter.
Ocugen Inc. (NASDAQ:OCGN) trade information
In the face of being in the red during last session for losing -12.79%, in the last five days OCGN remained trading in the green while hitting it’s week-highest on Monday, May 03 when the stock touched $16.20- price level, adding 32.65% to its value on the day. Ocugen Inc.’s shares saw a change of 496.17% in year-to-date performance and have moved -2.68% in past 5-day. Ocugen Inc. (NASDAQ:OCGN) showed a performance of 66.06% in past 30-days. Number of shares sold short was 34.77 Million shares which calculate 0.59 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $12.5 to the stock, which implies a rise of 14.57% to its current value. Analysts have been projecting $10 as a low price target for the stock while placing it at a high target of $15. It follows that stock’s current price would jump +37.49% in reaching the projected high whereas dropping to the targeted low would mean a loss of -8.34% for stock’s current value.
Ocugen Inc. (OCGN) estimates and forecasts
Statistics highlight that Ocugen Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added +3864.39% of value to its shares in past 6 months, showing an annual growth rate of 667.74% while that of industry is 8.6. Apart from that, the company came raising its revenue forecast for fiscal year 2021. The company is estimating its revenue growth to increase by 800% in the current quarter and calculating 294.7% increase in the next quarter. This year revenue growth is estimated to rise 1051807% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $78.1 Million for the same. And 2 analysts are in estimates of company making revenue of $78.1 Million in the next quarter that will end on June 01, 2021.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 70.8% during past 5 years. In 2021, company’s earnings growth rate is likely to be around 79% while estimates for its earnings growth in next 5 years are of 0%
Ocugen Inc. (NASDAQ:OCGN)’s Major holders
Insiders are in possession of 2.51% of company’s total shares while institution are holding 7.59% percent of that, with stock having share float percentage of 7.79%. Investors also watch the number of corporate investors in a company very closely, which is 65 institutions for Ocugen Inc. that are currently holding shares of the company. Vanguard Group Inc. (The) is the top institutional holder at OCGN for having 9.07 Million shares of worth $16.61 Million. And as of December 30, 2020, it was holding 4.82% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 2.23 Million shares on December 30, 2020. The number of shares represents firm’s hold over 1.18% of outstanding shares, having a total worth of $4.07 Million.
On the other hand, Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of December 30, 2020, the former fund manager was holding 6637849 shares of worth $12.15 Million or 3.53% of the total outstanding shares. The later fund manager was in possession of 4.92 Million shares on March 30, 2021, making its stake of worth around $33.37 Million in the company or a holder of 2.61% of company’s stock.